Surmodics shares are trading higher after the company announced it will be acquired by GTCR for $43 per share in cash for a total equity valuation of roughly $627 million.
Portfolio Pulse from Benzinga Newsdesk
Surmodics shares are trading higher following the announcement that the company will be acquired by GTCR for $43 per share in cash, valuing the company at approximately $627 million.
May 29, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics shares are trading higher after the announcement of its acquisition by GTCR for $43 per share in cash, valuing the company at approximately $627 million.
The acquisition announcement at a premium price of $43 per share is likely to drive SRDX stock higher in the short term as investors react positively to the buyout news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100